文献速递甲状腺疾病

Afirma基因组测序分类器在意义未明的不典型甲状腺结节二元亚分类中的表现:单次与重复诊断的比较

Performance of Afirma Genomic Sequencing Classifier in Binary Subcategories of Atypia of Undetermined Significance Thyroid Nodules: Single Versus Repeat Diagnosis.
PubMed 文献 · Thyroid · 2024-12-04

本研究回顾性分析365个单次或重复诊断为意义未明的不典型(AUS)且接受Afirma基因组测序分类器(GSC)检测的甲状腺结节,按2023 Bethesda系统分为AUS伴核异型(AUS-N)和其他不典型(AUS-O)。AUS-N结节的GSC良性呼叫率显著低于AUS-O结节,单次AUS组为43%对71%(p=0.001),重复AUS组为58%对74%(p=0.02)。单次与重复AUS队列之间的GSC诊断表现差异无统计学显著性。

要点

  • AUS-N结节的GSC良性呼叫率显著低于AUS-O结节。
  • 单次AUS组AUS-O结节的特异度显著高于AUS-N结节(73%对51%,p=0.01)。
  • 单次与重复AUS队列间的GSC表现差异无统计学显著性。

核心结论

  • GSC良性呼叫率和诊断表现在AUS-N与AUS-O亚分类之间可能不同。
  • 单次与重复AUS队列之间的GSC表现差异无统计学显著性。

研究设计与样本

  • 回顾性研究,分析连续甲状腺细针穿刺样本中单次或重复诊断为AUS且具有诊断性GSC结果(良性或可疑)的结节,共365个,其中AUS-N 106个、AUS-O 259个,随访手术干预或至少12个月临床和/或超声监测。

主要发现

  • GSC良性呼叫率在AUS-N结节中显著低于AUS-O结节:单次AUS组43%对71%(p=0.001),重复AUS组58%对74%(p=0.02)。
  • GSC可疑结果中组织学证实的恶性肿瘤比例在AUS-N结节中倾向于高于AUS-O结节:单次AUS组28%对10%(p=0.09),重复AUS组38%对27%(p=0.3)。
  • 单次AUS组中AUS-O结节的特异度显著高于AUS-N结节(73%对51%,p=0.01)。
  • 在两个亚分类中,重复AUS队列相比单次AUS队列具有更高的特异度、阳性预测值和诊断准确率,但差异未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Afirma Genomic Sequencing Classifier (GSC) testing has been utilized for further risk stratification of thyroid nodules categorized as atypia of undetermined significance (AUS). The 2023 Bethesda system subcategorizes AUS diagnosis into AUS with nuclear atypia (AUS-N) and other atypia (AUS-O). The current study aims to determine if performance of GSC testing differs between the two AUS subcategories and between single AUS cohort and repeat AUS cohort. Methods: This retrospective study analyzed consecutive thyroid nodule fine-needle aspiration with a single or a repeat AUS diagnosis and a diagnostic GSC testing result (benign vs. suspicious). All AUS nodules were divided into AUS-N or AUS-O subcategory and followed by either surgical intervention or at least 12 months of clinical and/or ultrasound monitoring. We then assessed performance of GSC testing in each subcategory and subsequently compared the individual performance in AUS-N or AUS-O subcategory between single AUS cohort and repeat AUS cohort. Results: The study identified a total of 365 thyroid nodules subcategorized as AUS-N (N = 106) and AUS-O (N = 259). Both cohorts showed a significantly lower GSC benign call rate (BCR) in AUS-N nodules compared with AUS-O nodules (43% vs. 71% in single AUS, p = 0.001; 58% vs. 74% in repeat AUS, p = 0.02). The proportion of histology-proven malignancies associated with a suspicious GSC result tended to be greater in AUS-N nodules than AUS-O nodules (28% vs. 10% in single AUS, p = 0.09; 38% vs. 27% in repeat AUS, p = 0.3). Compared with AUS-N nodules, AUS-O cohorts demonstrated significantly higher specificity in the single AUS group (73% vs. 51%, p = 0.01). In both subcategories, the repeat AUS cohort yielded greater specificity, positive predictive value, and diagnostic accuracy compared with the single AUS group. However, the differences did not reach statistical significance. Conclusions: GSC BCR and diagnostic performance of GSC testing may vary in AUS-N versus AUS-O subcategories. However, there were no statistically significant differences in GSC performance between single and repeat AUS cohorts.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jin X, Broome DT, Lew M, et al. Performance of Afirma Genomic Sequencing Classifier in Binary Subcategories of Atypia of Undetermined Significance Thyroid Nodules: Single Versus Repeat Diagnosis. Thyroid. 2024. PMID: 39630538. doi:10.1089/thy.2024.0277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。